New research from a team of genome scientists and DNA damage response experts breaks new ground in understanding the function of a protein currently limited in clinical trials for cancer treatments.

Olaparib in Patients With Solid Tumors With ATM Alterations: Results From the Targeted Agent and Profiling Utilization Registry (TAPUR) Study High levels of DNA replication stress and defects in the ...

I. Platinum-based therapies induce DNA inter-strand crosslinks (ICLs), which exacerbate genomic instability and impede DNA replication. In BRCA1/2-deficient tumor cells, the repair of these DNA ...

Researchers have uncovered a key mechanism that helps aging cells stop dividing before they can become cancerous, identifying the DNA damage sensor ATM as the central player in this process. Credit: ...

Results from early-stage clinical trials show two drugs that target the DNA damage response (DDR) pathway in cancers - ATR inhibitor elimusertib and PARP inhibitor AZD5305 - are safe and clinically ...